NASDAQ:XLRN - Acceleron Pharma Stock Price, Forecast & News

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Acceleron Pharma Inc (NASDAQ:XLRN) announced its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.83) by $0.03. The biopharmaceutical company had revenue of $4.20 million for the quarter, compared to analyst estimates of $4.44 million. Acceleron Pharma had a negative return on equity of 30.79% and a negative net margin of 353.57%. The business's revenue for the quarter was up 27.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.63) EPS. View Acceleron Pharma's Earnings History.

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Acceleron Pharma.

12 analysts have issued 12-month price objectives for Acceleron Pharma's stock. Their forecasts range from $45.00 to $88.00. On average, they anticipate Acceleron Pharma's share price to reach $62.91 in the next twelve months. This suggests a possible upside of 20.9% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.

Media headlines about XLRN stock have trended extremely negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acceleron Pharma earned a news sentiment score of -4.5 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Acceleron Pharma.

Acceleron Pharma saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 4,230,000 shares, a decline of 6.8% from the November 28th total of 4,540,000 shares. Based on an average trading volume of 359,500 shares, the days-to-cover ratio is presently 11.8 days. Currently, 9.4% of the company's shares are sold short. View Acceleron Pharma's Current Options Chain.

Some companies that are related to Acceleron Pharma include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), BioNTech (BNTX), Qiagen (QGEN), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO) and Iovance Biotherapeutics (IOVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Cisco Systems (CSCO), Gilead Sciences (Gild), LogicBio Therapeutics (LOGC), Intercept Pharmaceuticals (ICPT), Incyte (Incy), Intel (INTC), Corcept Therapeutics (CORT), Exelixis (EXEL) and Netflix (NFLX).

Acceleron Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.91%), Rhenman & Partners Asset Management AB (0.19%), Neville Rodie & Shaw Inc. (0.04%), Wealthstreet Investment Advisors LLC (0.04%), Zeke Capital Advisors LLC (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops and Sujay Kango. View Institutional Ownership Trends for Acceleron Pharma.

XLRN stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Neville Rodie & Shaw Inc., Zeke Capital Advisors LLC, Nisa Investment Advisors LLC and Wealthstreet Investment Advisors LLC. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin, Ravindra Kumar and Sujay Kango. View Insider Buying and Selling for Acceleron Pharma.

XLRN stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Strs Ohio and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XLRN stock can currently be purchased for approximately $52.05.

Acceleron Pharma has a market capitalization of $2.76 billion and generates $13.99 million in revenue each year. The biopharmaceutical company earns $-118,870,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.View Additional Information About Acceleron Pharma.

The official website for Acceleron Pharma is http://www.acceleronpharma.com/.

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]